Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 7/20 | 0.49 |
| ▸ | MTNR1B | P49286 | 7/20 | 0.49 |
| ▸ | NQO2 | P16083 | 6/20 | 0.49 |
| ▸ | ACHE | P22303 | 11/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9630654 | 0.82 | MTNR1A (0.65) | MTNR1AMTNR1BNQO2LMNAGAA | |
| SCHEMBL5738480 | 0.80 | HTR1A (0.42) | MTNR1AMTNR1BNQO2LMNA | |
| SCHEMBL5484579 | 0.80 | HTR1A (0.42) | MTNR1AMTNR1BNQO2LMNA | |
| SCHEMBL5739968 | 0.78 | HTR1A (0.53) | MTNR1AMTNR1BNQO2 | |
| SCHEMBL31277918 | 0.76 | PDE10A (0.47) | MTNR1AMTNR1BNQO2 | |
| SCHEMBL6260142 | 0.75 | HTR1A (0.43) | MTNR1AMTNR1BNQO2ACHELMNA | |
| SCHEMBL10586399 | 0.75 | CA12 (0.56) | MTNR1AMTNR1BNQO2ACHE | |
| SCHEMBL484623 | 0.74 | HTR1A (0.43) | MTNR1AMTNR1BNQO2 | |
| SCHEMBL485026 | 0.74 | MEN1 (0.48) | MTNR1AMTNR1BNQO2LMNAGAA | |
| SCHEMBL485027 | 0.74 | MEN1 (0.48) | MTNR1AMTNR1BNQO2LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150141384-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DEGENERATIVE DISORDERS | KANDULA MAHESH (US) | 2015-05-21 | — | — | US | disclosed |
| US-20150141384-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DEGENERATIVE DISORDERS | KANDULA MAHESH (US) | 2015-05-21 | — | — | US | disclosed |
| US-RE39616-E1 | Aminoindan derivatives | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2007-05-08 | — | — | US | disclosed |
| EP-1535902-A1 | Aminoindan derivatives | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2005-06-01 | — | — | EP | disclosed |
| EP-0966435-B1 | AMINOINDAN DERIVATIVES | TEVA PHARMA (IL) | 2005-04-06 | — | — | EP | disclosed |
| EP-0966435-A4 | AMINOINDAN DERIVATIVES | TEVA PHARMA (IL) | 2003-04-16 | — | — | EP | disclosed |
| US-6538025-B2 | Aminoindan derivatives | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2003-03-25 | — | — | US | disclosed |
| US-20020188020-A1 | Aminoindan derivatives | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM | 2002-12-12 | — | — | US | disclosed |
| US-6462222-B1 | TREATMENT OF DEMENTIAS OF THE ALZHEIMER TYPE AND MEMORY DISORDERS AS WELL AS ATTENTION DEFECIT DISORDERS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2002-10-08 | — | — | US | disclosed |
| US-6303650-B1 | FOR THERAPY OF ALZHEIMER'S DISEASE OR DEMENTIA | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2001-10-16 | — | — | US | disclosed |
| EP-0966435-A1 | AMINOINDAN DERIVATIVES | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1999-12-29 | — | — | EP | disclosed |
| WO-1998027055-A1 | AMINOINDAN DERIVATIVES | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1998-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141384-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DEGENERATIVE DISORDERS | HTT, SNCA, PARK7 | MTNR1A 228/4885MTNR1B 370/4885NQO2 3096/4885 |
| US-20020188020-A1 | Aminoindan derivatives | SNCA, HTR1A, HTR1D | MTNR1A 847/4885MTNR1B 1598/4885NQO2 1736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.